SSA
STML

Schonfeld Strategic Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Schonfeld Strategic Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-960,088
Closed -$4.65M – 1663
2020
Q1 		$4.65M Buy
960,088
+934,179
+3,606% +$6.06M 0.29% 65
2019
Q4 		$276K Sell
25,909
-40,491
-61% -$402K 0.01% 1017
2019
Q3 		$691K Sell
66,400
-524,000
-89% -$6.86M 0.02% 562
2019
Q2 		$9.04M Sell
590,400
-191,700
-25% -$2.77M 0.32% 74
2019
Q1 		$10.1M Buy
+782,100
New +$8.84M 0.35% 67

Schonfeld Strategic Advisors's STML Position: Q2 2020 in Review

Schonfeld Strategic Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 960,088 shares — an estimated $4.65M sold.

Schonfeld Strategic Advisors first reported a position in STML in Q1 2019 and held it in 5 quarters. The position peaked at $10.1M in Q1 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Schonfeld Strategic Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 960,088 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $4.65M.
  • Schonfeld Strategic Advisors first reported a position in Stemline Therapeutics, Inc. in Q1 2019 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Stemline Therapeutics, Inc. position peaked at $10.1M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.